Product
Cutaquig®
1 clinical trial
2 indications
Indication
Primary Immune Deficiency DisorderIndication
Secondary Immune DeficiencyClinical trial
Safety, Tolerability, and Patient Satisfaction of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment by Rapid Push in Patients With Primary or Secondary Immunodeficiency (PID or SID)Status: Recruiting, Estimated PCD: 2024-06-01